Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies.

[1]  P. Rémy,et al.  Heterogeneous pattern of renal disease associated with homozygous factor H deficiency. , 2011, Human pathology.

[2]  S. Nasr,et al.  Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement. , 2011, Clinical journal of the American Society of Nephrology : CJASN.

[3]  C. Sautès-Fridman,et al.  Alternative complement pathway assessment in patients with atypical HUS. , 2011, Journal of immunological methods.

[4]  R. Quigg,et al.  Complement factor H deficiency accelerates development of lupus nephritis. , 2011, Journal of the American Society of Nephrology : JASN.

[5]  S. Rodríguez de Córdoba,et al.  Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation. , 2010, The Journal of clinical investigation.

[6]  V. Frémeaux-Bacchi,et al.  C3 glomerulopathy: a new classification , 2010, Nature Reviews Nephrology.

[7]  E. Rondeau,et al.  Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. , 2010, Journal of the American Society of Nephrology : JASN.

[8]  C. Sautès-Fridman,et al.  Mutations in components of complement influence the outcome of Factor I-associated atypical hemolytic uremic syndrome. , 2010, Kidney international.

[9]  A. Blom,et al.  Mutations in complement factor I as found in atypical hemolytic uremic syndrome lead to either altered secretion or altered function of factor I , 2009, European journal of immunology.

[10]  D. Uhrín,et al.  The Binding of Factor H to a Complex of Physiological Polyanions and C3b on Cells Is Impaired in Atypical Hemolytic Uremic Syndrome1 , 2009, The Journal of Immunology.

[11]  John D Lambris,et al.  Structure of C3b-factor H and implications for host protection by complement regulators , 2009, Nature Immunology.

[12]  H. R. Bergen,et al.  Glomeruli of Dense Deposit Disease contain components of the alternative and terminal complement pathway. , 2009, Kidney international.

[13]  R. Salomon,et al.  Complement factor H deficiency and posttransplantation glomerulonephritis with isolated C3 deposits. , 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[14]  M. Walport,et al.  Factor I is required for the development of membranoproliferative glomerulonephritis in factor H-deficient mice. , 2008, The Journal of clinical investigation.

[15]  J. Atkinson,et al.  Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS), fatal Stx-HUS, C3 glomerulonephritis, and the HELLP syndrome. , 2007, Blood.

[16]  B. Boudailliez,et al.  Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. , 2007, Journal of the American Society of Nephrology : JASN.

[17]  U. Schlötzer-Schrehardt,et al.  Defective complement control of factor H (Y402H) and FHL-1 in age-related macular degeneration. , 2007, Molecular immunology.

[18]  D. Uhrín,et al.  Structure Shows That a Glycosaminoglycan and Protein Recognition Site in Factor H Is Perturbed by Age-related Macular Degeneration-linked Single Nucleotide Polymorphism* , 2007, Journal of Biological Chemistry.

[19]  M. Walport,et al.  Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains , 2007, The Journal of experimental medicine.

[20]  S. Bonsib,et al.  Dense deposit disease is not a membranoproliferative glomerulonephritis , 2007, Modern Pathology.

[21]  R. Salomon,et al.  A mutation in factor I that is associated with atypical hemolytic uremic syndrome does not affect the function of factor I in complement regulation. , 2007, Molecular immunology.

[22]  G. Remuzzi,et al.  The interactive Factor H–atypical hemolytic uremic syndrome mutation database and website: update and integration of membrane cofactor protein and Factor I mutations with structural models , 2007, Human mutation.

[23]  U. Schlötzer-Schrehardt,et al.  MPGN II – genetically determined by defective complement regulation? , 2007, Pediatric Nephrology.

[24]  R. Salomon,et al.  Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome , 2006, Journal of Medical Genetics.

[25]  G. Remuzzi,et al.  Complement Factor H Gene Abnormalities in Haemolytic Uraemic Syndrome: From Point Mutations to Hybrid Gene , 2006, PLoS medicine.

[26]  Victoria A. Higman,et al.  His-384 Allotypic Variant of Factor H Associated with Age-related Macular Degeneration Has Different Heparin Binding Properties from the Non-disease-associated Form* , 2006, Journal of Biological Chemistry.

[27]  G. Remuzzi,et al.  Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. , 2006, Blood.

[28]  M. Little,et al.  Severity of primary MPGN, rather than MPGN type, determines renal survival and post-transplantation recurrence risk. , 2006, Kidney international.

[29]  J L McRae,et al.  Variations in the complement regulatory genes factor H (CFH) and factor H related 5 (CFHR5) are associated with membranoproliferative glomerulonephritis type II (dense deposit disease) , 2005, Journal of Medical Genetics.

[30]  G. Eknoyan,et al.  Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). , 2005, Kidney international.

[31]  R. T. Smith,et al.  A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[32]  John D Lambris,et al.  Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. , 2005, Journal of the American Society of Nephrology : JASN.

[33]  A. Buil,et al.  Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32. , 2005, Human molecular genetics.

[34]  H. Deng,et al.  The development of atypical haemolytic-uraemic syndrome is influenced by susceptibility factors in factor H and membrane cofactor protein: evidence from two independent cohorts , 2005, Journal of Medical Genetics.

[35]  L. Bostad,et al.  Prognostic factors in mesangioproliferative glomerulonephritis. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[36]  M. Walport,et al.  Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H , 2002, Nature Genetics.

[37]  N. Gretz,et al.  Complement analysis in children with idiopathic membranoproliferative glomerulonephritis: A long‐term follow‐up , 2001, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[38]  S. Meri,et al.  Each of the three binding sites on complement factor H interacts with a distinct site on C3b. , 2000, The Journal of biological chemistry.

[39]  J. H. Jansen,et al.  Hereditary porcine membranoproliferative glomerulonephritis type II is caused by factor H deficiency. , 1995, The Journal of clinical investigation.

[40]  G. Schwartz,et al.  A simple estimate of glomerular filtration rate in adolescent boys. , 1985, The Journal of pediatrics.

[41]  D. J. Langford,et al.  A simple estimate of glomerular filtration rate in full-term infants during the first year of life. , 1984, The Journal of pediatrics.

[42]  C. Swainson,et al.  Mesangiocapillary glomerulonephritis: A long‐term study of 40 cases , 1983, The Journal of pathology.

[43]  G. Haycock,et al.  Idiopathic mesangiocapillary glomerulonephritis. Comparison of types I and II in children and adults and long-term prognosis. , 1983, The American journal of medicine.

[44]  F. Schena,et al.  Biological significance of the C3 nephritic factor in membranoproliferative glomerulonephritis. , 1982, Clinical nephrology.

[45]  G. Schwartz,et al.  A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. , 1976, Pediatrics.

[46]  O. Llorca,et al.  Lessons from functional and structural analyses of disease-associated genetic variants in the complement alternative pathway. , 2011, Biochimica et biophysica acta.

[47]  V. D’Agati,et al.  Dense deposit disease: clinicopathologic study of 32 pediatric and adult patients. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[48]  M. Kazatchkine,et al.  Selective disappearance of C3NeF IgG autoantibody in the plasma of a patient with membranoproliferative glomerulonephritis following renal transplantation. , 1994, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[49]  M. Kazatchkine,et al.  Protection of the classical and alternative complement pathway C3 convertases, stabilized by nephritic factors, from decay by the human C3b receptor , 1984, European journal of immunology.

[50]  C. Bazzi,et al.  The prognostic value of some clinical and histological parameters in membranoproliferative glomerulonephritis (MPGN): report of 112 cases. , 1977, Nephron.

[51]  J. Berger.  Complement deposition in the kidney. , 1974, Advances in nephrology from the Necker Hospital.